... of FineTech Laboratories, Ltd. and a $9.2 million asset impairment charge related to Par's purchase of the new drug application (NDA) for Isoptin(R) SR. ...
Ranbaxy commercialised its first authorised generic product, Isoptin SR (Verapamil SR) in the US market two days ago. It hopes to garner a good share of the ...
New Delhi, July 30: Ranbaxy Laboratories has commercialised its first authorised generic product, Isoptin SR — an anti-hypertensive agent — in the US market ...
BO: Quote, Profile, Research) said on Monday it had launched its first authorised generic drug, Isoptin SR, in the US market, after an agreement with FSC ...
Isoptin® SR, a niche value added formulation, also enhances our New Drug Delivery systems (NDDS) capability and our efforts with other molecules, ...
30, 2007, announced that its first Authorized Generic (AG) product, Isoptin SR (Verapamil Sit) will be commercially available in the US market. ...
"The commercialisation of Ispotin SR heralds Ranbaxy's entry into the authorised generics space. Isoptin SR, a niche value added formulation, also enhances ...
Ranbaxy Laboratories Ltd July 30, 2007 announced the commercialization of its first Authorized Generic (AG) product, Isoptin® SR (Verapamil Sit) in the US ...
Mumbai: Ranbaxy Laboratories has announced the commercialisation of its first authorised generic (AG) product, Isoptin SR (Verapamil SR) in the US market, ...
... company Ranbaxy Laboratories Ltd said it has started the production and sale of its first authorised generic drug Isoptin SR (Verapamil Sit) in the US. ...